Valneva Austria GmbH
Records under this name other than the patents Valneva Austria GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 27 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,357,557 | Isolated Polypeptide of the Toxin a and Toxin B Proteins of C. Difficile and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 10,821,166 | Isolated Polypeptide of the Toxin a and Toxin B Proteins of C. Difficile and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,357,844 | Isolated Polypeptide of the Toxin a and Toxin B Proteins of C. Difficile and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,478,540 | Isolated Polypeptide of the Toxin a and Toxin B Proteins of C. Difficile and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 12,324,831 | Isolated Polypeptide of the Toxin a and Toxin B Proteins of C. Difficile and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 9,598,472 | Isolated Polypeptide of the Toxin a and Toxin B Proteins of C. Difficile and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,684,669 | CpG-ADJUVANTED SARS-CoV-2 VIRUS VACCINE Formerly held In force · High confidence | In force | High confidence | |
| US 7,704,514 | Vaccines Term ended Term ended Jan 15, 2026 · High confidence | Term ended | Term ended Jan 15, 2026 | High confidence |
| US 8,900,564 | Vaccine Composition Comprising An Antigen And A Peptide Having Adjuvant Properties Term ended Term ended Dec 9, 2024 · High confidence | Term ended | Term ended Dec 9, 2024 | High confidence |
| US 8,784,837 | Vaccines Comprising an Immunostimulatory Peptide and an Immunostimulatory Oligodeoxynucleic Acid Molecule Term ended Ended no later than May 10, 2024 · Medium confidence | Term ended | Ended no later than May 10, 2024 | Medium confidence |